Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette-Guerin therapy: Correlation to clinical outcome Academic Article uri icon

Overview

MeSH Major

  • BCG Vaccine
  • Neoplasm Proteins
  • Tumor Suppressor Protein p53
  • Urinary Bladder Neoplasms

abstract

  • In this high-risk population of patients with superficial bladder tumors, patients who have p53 nuclear overexpression in the tumor and stage T1 disease before BCG therapy are at high risk of disease progression. Furthermore, in the group of patients with residual disease after BCG therapy, p53 status is a better predictor of disease progression than post-BCG stage.

publication date

  • October 12, 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8874323

Additional Document Info

start page

  • 2646

end page

  • 52

volume

  • 14

number

  • 10